Introduction
The aim of these recommendations is to promote uniformity between radiotherapy centres, when reporting their treatments. It is, indeed, essential, when exchanging information, that the same type of treatment be reported in the same way from different centers, using the same terminology and definitions.
These recommendations deal with volumes and doses. They are valid for photon beams.
General Recommendations for Reporting Volumes

Gross Tumor Volume
The primary aim of the clinical work-up of a patient with a malignant disease is to define the site of the primary tumor, its size and possible invasion of adjacent structures, and to detect regional lymph node involvement and distant metastases. This staging procedure should result in an accurate assessment of the extent of disease. As this is a purely anatomical concept, it can be accurately described in standard topographic terms, e.g., "tumor in the roof of nasopharynx with metastatic nodes in the sternomastoid chain bilaterally in the neck." This constitutes the description of the Gross Tumor Volume.
In many situations, a verbal description might be too cumbersome, and, also, for the purpose of data recording and analysis, a classification is needed. For the purpose of recording and documentation, it might thus be necessary to codify this anatomical description.
There are several systems for coding anatomy. The system probably most widely used at present for describing the site of the primary tumor is Chapter 2 (Neoplasia) of the 9th edition of the ICD (International Classification of Diseases) (WHO, 1977) . This code can be supplemented by a TNM-or pTNMclassification, indicating the extent of the malignant disease (UICC, 1987 (UICC, , 1990 . However, since the ICD code was designed for the purpose of epidemiology and health care statistics, it is not a pure topographic descriptor, and has been modified for oncological purposes in the ICD-O (WHO, 1976a , 1990 code. By means of this code, it might be possible to describe the Gross Tumor Volume and Clinical Target Volume in most situations, but it does not allow for a sufficiently detailed description of a number of different structures (e.g., lymph nodes) . Furthermore, laterality for paired organs and structures must be indicated by a supplementary code.
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Another coding system is the SNOMED (Systematized Nomenclature of Medicine) (CAP, 1979) in which the section on topography (T-SNOMED) contains a suitable but rather complex code.
A comprehensive code for anatomical sites based on ICD-O(10) (WHO, 1990) is suggested in Appendix I, Table 1 .2. A simple code for description of sections is suggested in Appendix I, Table 1.3. Schematic examples of how to utilize these coding systems to describe volumes, viz., the Gross Tumor Volume and Clinical Target Volume, for recording and documentation purposes are given for four typical clinical situations in Appendix I, Fig. 1.1 .
For reporting purposes, however, a description in plain language is recommended.
Clinical.Target Volume
The Clinical Target Volume is also a purely anatomical concept and can, in addition to any existing tumor, be described as including structures with clinically suspected but not proven involvement. Thus, the Clinical Target Volume cannot be defined a priori in terms of a TNM or pTNM classification, but must be defined in plain topographic terms or according to a corresponding code in conformity with the recommendations for GTV. Examples are to be found in Appendix I.
Planning Target Volume
Since the Planning Target Volume is defined to take variations in size and position of the Clinical Target Volume into account, it is a purely geometric concept, and thus cannot be described in anatomic terms. The recommendations are that the PTV is described by giving the size of the margins around the CTV in all relevant directions. A desirable development could be the possibility of defining the PTV in terms of coordinates in a patient related coordinate system (Report 42 [ICRU, 1987] ).
Treated Volume '
The definition of the Treated Volume is that volume enclosed within a specified isodose envelope, and thus the description ofthis volume for reporting must indicate which isodose level was selected or, preferably, the corresponding absorbed dose value (Gy) and, if possible, an estimation of the size of that volume (cm 3 ). 
Irradiated Volume
Recommended Recommended
Recommended
In conformity with the Treated Volume, the Irradiated Volume is also defined by a specified isodose envelope and, for reporting purposes, the value of the isodose chosen, or, preferably, the corresponding Recommended Recommended Recommended 3.l.d, 3.l.e, 3.l.f, 2.5.b, 2.5.c 3.l.g 3.l.h 3.2, 3.3, 3.4 absorbed dose value (Gy) should be given. Also, an estimation of the size of the volume (cm 3 ) should be reported.
An illustration of the variation in size of the Treated Volume and Irradiated Volume with differ- Fig 
General Recommendations for Reporting Doses
The dose at or near the center of the Planning Target Volume as well as the maximum and the minimum dose to the PTV shall be reported. Additional information (such as average dose, dose / volume histograms), when available, may be useful.
The ICRU Reference Point
The present system of recommendations for reporting is based on the selection of a point within the PTV, which is referred to as the ICRU Reference Point.
The ICRU Reference Point shall be selected according to the following general criteria:
the dose at the point should be clinically relevant and representative of the dose throughout the Planning Target Volume (PTV); the point should be easy to define in a clear and unambiguous way;
ANT the point should be selected where the dose can be accurately determined (physical accuracy) ; the point should be selected in a region where there is no steep dose gradient. These recommendations will be fulfilled if the ICRU Reference Point is located firstly at the center, or in the central part, of the Planning Target Volume, and secondly on or near the central axis of the beam(s).
The method of selection of the ICRU Reference Point is best illustrated by practical examples. Some recommended ICRU Reference Points for simple beam arrangements are listed in Table 3 .1. and demonstrated in Fig. 3 .1. They are located on the beam axes, or at the intersection of the beam axes (if such an intersection point exists inside the Planning Target Volume, and provided it is located in the central part of the Planning Target Volume, i.e., at least about 2 em inside the border of the PTV), or only in the central part of the PTV.
In some situat~ons, the conditions do not allow for the ICRU Reference Point to be localized both at or near the center of the PTV, and also on the beam axis in an area where the dose distribution is homogeneous. In these cases, the first criterion, i.e., localiza- In other situations, it will be found that the "center of the PTV" will not be a meaningful concept, if it is taken to imply the purely geometrical center or the center of gravity. Such a definition could result in the "center" being outside the tissues represented by the PTV (e.g., when treating the chest wall, where the center of gravity of the PTV may be in healthy lung tissue, or, in the case of treatment of the regional lymph nodes of a pelvic tumor, where the PTV may be ring-shaped, and its center of gravity is not in the tissue concerned). In these cases, one has to select the ICRU Reference Point inside the tissues represented by the PTV, and in a place where dose specification is considered to be meaningful. Such a place could be the region where the tumor cell density is considered to be at its maximum. An example is given in Appendix II, Fig. II.3 .c. Wherever the ICRU Reference Point is localized, it must be clearly specified.
The ICRU Reference Dose
The dose at the ICRU Reference Point is the ICRU Reference Dose, and should always be reported.
The Dose Variation Throughout the Planning Target Volume
As previously indicated (Section 2.4.1.), a certain degree of inhomogeneity of the absorbed dose throughout the Planning Target Volume (PTV) cannot be avoided (i.e., the dose varies from the maximum dose value to the minimum dose level).
As a minimum requirement, the maximum dose and the minimum dose to the PTV shall be reported, together with the dose at the ICRU Reference Point. The three dose values then indicate the dose to the Clinical Target Volume and the dose variation.
The maximum dose is also relevant in relation to possible side effects.
The minimum dose is considered to be relevant in relation to tumor control. The isodose corresponding to the same value is sometimes called the "minimum isodose envelope." However, it cannot be used as the sole predictor of tumor control due to possible ambiguity in the definition of the border of the Clinical Target Volume (where, by definition, the tumor cell concentration should be zero). Tumor control may be more likely determined by the dose level in the GTV where tumor cell density is large. Furthermore, there are large dose compilation uncertainties near or in the penumbra region, where the dose gradient is steep.
Other dose values considered to be relevant (e.g., average dose and its standard deviation, dose areal volume histograms, biologically weighted doses), when available, should also be reported.
An analysis of the relative merits of using different types of doses for reporting is given in Appendix III.
The Three Levels of Dose Evaluation for Reporting
The level of completeness and accuracy of reporting therapeutic irradiation depends to a large extent on the situation in the department and on the aim of the treatment. For different clinical and practical considerations, different levels of ambition for dose evaluation can be identified. Three levels have been selected for reasons given below, but it is recognized that intermediate levels could also be identified.
3.3.4.1 Levell: Basic Techniques. The minimum requirements for reporting can be followed in all centers, including those with restricted therapy equipment, dosimetric, computer, and staff facilities. This minimum level may sometimes be sufficient, in any center, when simple treatments are performed (e.g., some palliative treatments). At this level, it is assumed that the dose at the ICRU Reference Point and an estimate ofthe maximum and minimum doses to the PTV can be determined using, e.g., central axis depth dose tables. Some information about the dose outside the beam axis could also be obtained by means of standard isodose charts.
3.3.4.2 Level 2: Advanced Techniques. The standards of dose planning at this level allow the exchange between different centers of more complete and relevant information. At this level, it is assumed that the GTV, CTV, and PTV can be defined in one or more planes (sections), using reliable patient data acquisition tools, and/ or modern imaging techniques under reliable conditions (e.g., a series of CT and/or MRI sections). It is also assumed that complete dose distributions are computed in the central plane and in other planes (sections) using only central plane dose data, and with inhomogeneity corrections, when appropriate.
3.3.4.3 Level 3: Developmental Techniques. The performance of dose planning at level 3 provides for the development of new techniques and clinical research in radiotherapy. At this level, 3-D dose computation of any beam arrangement (such as non-coplanar beams) and dose-volume histograms are available.
NB: In summary, the 3 levels could be described as follows:
Levell: only the dose at the ICRU Reference Point and its variation along a central beam axis is available. Level 2: the dose distribution can be computed for plane(s). Fig. 3.2 . Example of a technique for radiotherapy after breast conserving surgery in node positive patients. There are two topographically separate PTVs, namely, the breast (dotted line in section II, Fig. 3.2 .c) and regional lymph nodes in axilla and supraclavicular fossa (dotted line in section I, Fig. 3.2.b ). An overview of the beam arrangements is given in Fig. 3.2 .a. The treatment machine is equipped with asymmetric jaws, which are used to shield to the midline in each beam, producing the four 5·MV·photon beams (two tangential [Nos. 1 and 2] to the breast, and two AP·PA [Nos. 3 and 4] towards the lymph nodes in the axilla and supraclavicular fossa). All four beams have the same isocenter (circle with cross), and all beams thus have a common border through the isocenter. Thus, there is no central axis within any of the beams. Additional parts of the beams are shielded and shown as hatched areas. The 100%, 95%, and 105% isodose lines are given, normalized to the ICRU Reference Points for the two PTVs (as indicated by the triangle [breast] and the square [regional lymph nodesD. A dose of 50 Gy is given to each of these PTVs according to the ICRU Reference Points (100% isodose lines).
-~}-. ::::... Level 3: the dose distribution can be computed for volumes. At any level, the dose at the ICRU Reference Point and the best estimation of the maximum and the minimum dose to the PTV should be reported. In addition, this information could be supplemented by, e.g., isodose plans, dose-area/volume histograms, and other information, when available, at levels 2 or 3.
A Single Planning Target Volume
Simple Beam Arrangements
The way to select the ICRU Reference Point is illustrated in Fig. 3.1 for a series of typical simple beam arrangements. The ICRU Reference Point is located centrally in the PTV on the beam axes at their intersection (provided that such an intersection point exists and that it is located in the central part of the PTV, or at least well inside the border of the PTV). The dose to the ICRU Reference Point as well as the maximum and the minimum dose to the PTV should be reported.
Several of the simple beam arrangements, considered in Fig. 3.1 ., are used in a large proportion of treatments, especially for palliation.
Complex Beam Arrangements
In some situations, the ICRU Reference Point cannot be selected according to the basic criteria given in section 3.3.1, for instance: non-coaxial parallel opposing or non-opposing beams (e.g., different beam sizes or parallel beams), non-coplanar beams, beam intersection outside (or at the outer part oD the PTV. In such situations, the ICRU Reference Point will have to be selected according to the additional criteria given in section 3.3.1.
The .... Fig. 3.3 . Treatment of a thyroid carcinoma with mediastinal involvement using coplanar beams whose central rays do not intersect at one point. The purpose of treatment was to deliver 60 Gy to the thyroid and anterior mediastinum and to keep the dose to the cord below 42 Gy. Only anterior beams were used: their weight is expressed by their dose contribution to the ICRU Reference Point (triangle) and, for the electron beam, to the 60 Gy isodose in the sagital median plane. The PTV is indicated by the dotted line. The isodose lines indicate absolute values (Gy). The ICRU Reference Point is indicated by the triangle. The dose specified for reporting is 60 Gy, with the variation from 69 Gy to 47 Gy. Modified from Report 29 [lCRU, 1978l. 
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Complex Treatments with More Than
One Planning Target Volume
Introduction
With the increasing complexity of radiotherapy treatments, more than one Planning Target Volume is frequently identified. In practice, the two most common situations are adjacent PTVs and overlapping PTVs (Fig. 3.5.) .
Adjacent Planning Target Volumes
In this situation, the PTVs are adjacent to each other; they do not overlap. A typical example may be the postoperative treatment of breast cancer including the breast and chest wall, and the regional lymphatics (see Fig. 3 .2., and Appendix I, Fig. l.l.b.) .
When the PTVs are adjacent to each other, as a minimum requirement, the dose to each PTV (at its ICRU Reference Point, as well as the maximum and the minimum dose to each PTV) should be reported as indicated in section 3.4.1. Note that since treatment of one PTV may give a dose contribution to the other PTV, reporting at level 1 may give information that does not take this into consideration. Information obtained at levels 2 and 3 (e.g., isodoses, dosearea/ volume histograms) will increase the usefulness of the information.
Overlapping Planning Target Volumes
In this situation, one PTV is totally contained within the confines of the other. A typical example is the "boost" technique. In this case, again, two situations may occur: the beam axes of the two PTVs are identical and the centers coincide (see Appendix II, Figs. II.3.a. and b.). the centers of the two PTV s and the beam axes differ (see Appendix II, Fig. 11.2.) . NB: The "shrinking field technique" can be considered as consisting of a series of smaller PTVs inserted into each other.
When the PTVs are overlapping the following procedures are recommended: beams whose central rays do not intersect at one point, non-coplanar beams, and opposed noncoaxial beams. The weighting of the beams was chosen to give the prescribed total absorbed dose in the two PTVs with the same number offractions. The distribution of the absorbed dose is calculated firstly for PTV I and the cranial part of the PTV II in a frontal section (I) and then a dose plan is produced for the spinal part of the PTV II in a median sagittal section (II) . Furthermore, in order to evaluate the kidney dose, a transverse section (Ill) was also used. For reporting, three different ICRU Reference Points are defined, namely, one for the PTV I (e = ICRU 1), two (. = ICRU 2, and.a, = ICRU 3, respectively) for the cranial and spinal parts of the PTV II, respectively. From Report 29 [ICRU, 19781. Fig. 3.5 . Two different Planning Target Volumes which may be: a. Adjacent to each other. b. One totally contained within the confines of the other with coinciding centers and identical beam axes. c. One totally contained within the confines of the other but different centers of the PTVs and the beam axes. @ = PTVI@ = PTVII ence Point and the maximum and minimum dose to each PTV for each part of the treatment are calculated along the central beam axes and should be reported accordingly. At levell, the report is confined to a simple description of technique.
3.5.3.2 At Levels 2 and 3. The dose distributions for each PTV are calculated and added and the dose to each ICRU Reference Point, as well as the maximum and minimum dose for each PTV, are reported, taking into account the cumulative contribution to each PTV. For the smaller PTV, the criteria of central position of the ICRU Reference Point in the PTV can usually be met. For the larger PTV (see Appendix II, Fig. 11.3.) , an ICRU Reference Point has to be selected according to criteria given in section 3.3.1. (i.e., at a specially selected position considered to be significant for tumor control in this PTV).
Organs at Risk
For each organ at risk, the maximum dose, together with the volume of the organ receiving that dose, should, when possible, be reported, (e.g., maximum spinal cord dose 42 Gy, 10 cm C1-C4, or left kidney dose 21 Gy, whole kidney).
In some situations, part of the organ or even the whole organ is irradiated to doses above the accepted tolerance level. In that case, the volume that receives at least the tolerance dose should be estimated.
When reporting at Level 3 is possible, dose-volume histograms for organs at risk, average doses, biologically weighted quantities, etc. could also be reported.
Hot Spots
If a hot spot (see section 2.4.8.) occurs, its size and position should be reported.
